Telix Group inks deal with ININ to boost prostate imaging technology
Category: #health  By Pankaj Singh  Date: 2019-01-24
  • share
  • Twitter
  • Facebook
  • LinkedIn

Telix Group inks deal with ININ to boost prostate imaging technology

Telix Pharmaceuticals Limited, through its wholly-owned subsidiary Advanced Nuclear Medicine Ingredients SA (ANMI), has recently announced that it has entered into an agreement with Mexico’s Instituto Nacional de Investigaciones Nucleares (ININ) and completed the in-licensing of ININ’s 99mtechnetium-EDDA/HYNIC-Lys (NaI)-Urea-Glu (99mTc-iPSMA). Apparently, the product is an innovative clinical-stage radiopharmaceutical for prostate cancer imaging.

According to Telix, Single Photon Emission Computed Tomography, termed as SPECT, is widely deployed nuclear medicine imaging procedure, particularly for managing cancer, being an alternative to the Positron Emission Tomography or PET approach already being developed by ANMI. SPECT, even though similar to PET with regards to radioactive trace usage and gamma ray detection, is the dominant nuclear imaging modality in cancer management due to less availability of PET/CT worldwide.

Sources close to the matter informed that the team of ININ and its partners have been able to clinically evaluate 99mTc-iPSMA with SPECT/CT, the results of which show highly sensitive detection of lesions in prostate cancer. There is considerable commercial and clinical potential of the product for evaluating both primary disease and metastases in regions where extensive PET infrastructure is not present.

Reportedly, 99mTc-iPSMA has strong international patent protection in several commercial markets. 99mTc-iPSMA has been developed as result of world-class research performed by innovative ININ research group from the National Laboratory on Research and Development of Radiopharmaceuticals (LANIDER), sources mentioned. The group has substantial experience in the nuclear medicine field. 

Through scientific partnerships with the National Laboratories of the National Council of Science and Technology (CONACyT) and Mexican National Institute of Cancerology (INCan), LANIDER group maintains numerous international and national collaborations.

For the record, Telix is headquartered in Melbourne and has operations internationally in the U.S., Japan and EU. Telix’s license agreement with ININ represents a worldwide agreement and also includes a partnership for manufacturing the product.



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

RADLogics obtains FDA's approval for AI-based chest X-Ray App
RADLogics obtains FDA's approval for AI-based chest X-Ray App
By Pankaj Singh

RADLogics Inc., a healthcare software company developing AI-powered solutions has reportedly received 510(k) clearance from the US FDA (Food and Drug Administration) for its latest AI-Powered chest X-ray pneumothorax a...

CDE of China NMPA clears I-Mab’s application for lemzoparlimab
CDE of China NMPA clears I-Mab’s application for lemzoparlimab
By Pankaj Singh

Clinical stage biopharmaceutical major, I-Mab, has reportedly announced that it has received the clearance of the Center for Drug Evaluation of the China National Medical Products Administration for its IND application...

Aoyuan Healthy to acquire 55% equity interest in Liantianmei
Aoyuan Healthy to acquire 55% equity interest in Liantianmei
By Pankaj Singh

Aoyuan Healthy Life Group Company Ltd., a renowned commercial property operation service and property management service provider based in China, has reportedly announced that Guangdong Xinyuerong Industrial Investment...